News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
3,349 Results
Type
Article (883)
Company Profile (2)
Press Release (2464)
Multimedia
Podcasts (18)
Webinars (1)
Section
Business (1442)
Career Advice (20)
Deals (189)
Drug Delivery (11)
Drug Development (617)
Employer Resources (11)
FDA (103)
Job Trends (180)
News (2038)
Policy (149)
Tag
Academia (11)
Accelerated approval (3)
ADA (1)
Alliances (185)
ALS (2)
Alzheimer's disease (8)
Antibody-drug conjugate (ADC) (1)
Approvals (94)
Artificial intelligence (5)
Autoimmune disease (10)
Bankruptcy (2)
Best Places to Work (111)
BIOSECURE Act (2)
Biosimilars (1)
BioSpace Insights (3)
Biotechnology (1)
Breast cancer (1)
Cancer (17)
Cardiovascular disease (7)
Career advice (17)
CAR-T (7)
CDMO (7)
Cell therapy (25)
Clinical research (433)
Collaboration (14)
Compensation (4)
Complete response letters (2)
COVID-19 (14)
CRISPR (36)
C-suite (37)
Cystic fibrosis (44)
Data (35)
Diabetes (9)
Diagnostics (5)
Diversity, equity & inclusion (2)
Drug discovery (6)
Drug pricing (11)
Duchenne muscular dystrophy (7)
Earnings (399)
Editorial (3)
Employer branding (6)
Employer resources (9)
Events (478)
Executive appointments (20)
FDA (122)
Funding (28)
Gene editing (57)
Gene therapy (54)
GLP-1 (20)
Government (40)
Guidances (4)
Healthcare (46)
Hematology (1)
Huntington's disease (2)
IgA nephropathy (22)
Immunology and inflammation (9)
Immuno-oncology (2)
Indications (1)
Infectious disease (14)
Intellectual property (1)
Interviews (3)
IPO (57)
Job creations (68)
Job search strategy (13)
JPM (2)
Kidney disease (11)
Labor market (4)
Layoffs (8)
Leadership (3)
Legal (18)
Lung cancer (4)
Lymphoma (1)
Management (1)
Manufacturing (9)
Medical device (15)
Medtech (15)
Mergers & acquisitions (136)
Metabolic disorders (20)
mRNA (10)
Multiple sclerosis (2)
Neurodegenerative disease (6)
Neuropsychiatric disorders (1)
Neuroscience (22)
NextGen: Class of 2026 (51)
Non-profit (14)
Now hiring (4)
Obesity (10)
Opinion (14)
Pain (33)
Parkinson's disease (1)
Partnered (1)
Patents (1)
Patient recruitment (2)
People (667)
Pharmaceutical (1)
Phase 1 (155)
Phase 2 (235)
Phase 3 (163)
Pipeline (68)
Policy (15)
Postmarket research (18)
Preclinical (36)
Radiopharmaceuticals (2)
Rare diseases (102)
Real estate (57)
Recruiting (4)
Regulatory (164)
Research institute (5)
Resumes & cover letters (5)
RNA editing (1)
RSV (1)
Schizophrenia (2)
Series A (6)
Series B (4)
Sickle cell disease (38)
Special edition (3)
Spinal muscular atrophy (1)
Startups (36)
Supply chain (1)
Tariffs (6)
The Weekly (18)
Vaccines (10)
Venture capital (7)
Weight loss (5)
Date
Last 7 days (7)
Last 30 days (20)
Last 365 days (201)
2026 (171)
2025 (218)
2024 (270)
2023 (222)
2022 (231)
2021 (254)
2020 (260)
2019 (197)
2018 (183)
2017 (221)
2016 (137)
2015 (210)
2014 (79)
2013 (67)
2012 (88)
2011 (122)
2010 (67)
Location
Africa (13)
Alabama (1)
Asia (98)
Australia (19)
California (50)
Canada (18)
China (16)
Colorado (1)
Europe (529)
Illinois (4)
Japan (2)
Maryland (9)
Massachusetts (225)
Minnesota (1)
Montana (1)
New Hampshire (5)
New Jersey (6)
New York (15)
North Carolina (10)
Northern California (22)
Ohio (2)
Pennsylvania (5)
South America (13)
Southern California (21)
Tennessee (1)
Texas (3)
United States (326)
Utah (1)
Virginia (1)
Washington State (5)
3,349 Results for "vertex".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cystic fibrosis
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
August 10, 2026
·
2 min read
·
Michael Gibney
Clinical research
Vertex opens up larger kidney disease opportunity with mid-stage readout
While Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a different kidney disease.
September 22, 2026
·
3 min read
·
Annalee Armstrong
IgA nephropathy
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
The FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for their recently approved IgAN therapies Fabhalta and Trutakna.
July 20, 2026
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vertex unfazed by competitive IgAN space as FDA verdict looms
Positive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said on the company’s second quarter earnings call.
August 4, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Vertex inks $10B Crinetics buy, entering ‘white space blockbuster opportunity’
Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals is the largest pickup in the company’s history, according to analysts at BMO Capital Markets.
July 7, 2026
·
2 min read
·
Tristan Manalac
Earnings
Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution
While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.
May 5, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Vertex Appoints Daniel Brennan to its Board of Directors
October 20, 2026
·
2 min read
Earnings
All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts
Analysts are keeping a close eye on Vertex’s kidney disease portfolio, anchored by the IgAN drug povetacicept, as its nonopioid painkiller Journavx is poised for “incremental” growth in the first half 2026, according to BMO Capital Markets.
February 13, 2026
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetacicept in IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the end of March.
March 10, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
October 7, 2026
·
1 min read
1 of 335
Next
